Results 151 to 160 of about 13,952 (268)

The principles of systems biology. [PDF]

Exp Physiol
Noble D, Bourret R.
europepmc   +1 more source

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source

How should we teach homeostasis? Filling the gaps and envisioning the future. [PDF]

Front Physiol
Kuang SY, Naik AR.
europepmc   +1 more source

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source

Effectiveness and Persistence of Long-Acting Injectable Cabotegravir and Rilpivirine in Migrant Individuals Living With HIV in Spain: Substudy of the RELATIVITY Cohort. [PDF]

J Int AIDS Soc
Llenas-García J, Arcos Rueda MDM, Calderón Hernaiz R, Pedrero Tomé R, Bisbal Pardo O, Matarranz M, Torralba M, Galindo Puerto MJ, Rodríguez A, Peñaranda Vera M, Sanjoaquín Conde I, de la Fuente Moral S, Cabello-Úbeda A, Navarro San Francisco C, Antelo Cuéllar K, Pedrosa Aragón M, Aguilera García M, Tiraboschi J, Martínez Álvarez RM, Vivancos MJ, Montero Hernández C, Bernal Morell E, Cabello-Clotet N, Morano Amado LE, Gisbert Pérez L, Sepúlveda MA, Alemán Valls MR, Sánchez Guirao AJ, Fanciulli C, Escrig C, Ferreira Pasos EM, Lucas-Dato A, García Torras S, Hidalgo Tenorio C, Estébanez M, Muelas-Fernandez M, Losa García JE, Cerezales Calviño A, Pino Díaz ME, Martínez Montes C, Arenas García V, Arnaiz de Las Revillas F, Pernas Pardavila H, Padilla S, Garcinuño Jiménez MÁ, Alonso Alonso L, Ramos Vicente N, Barragán Gallo PN, Cabo Magadan R, Del Álamo M, Egido Murciano MV, Juárez Toquero A, Romero Palacios A, Clavero Olmos M, García Navarro MDM, Sanz J, Gainzarain JC, Milian Sanz M, de la Calle B, Ferrero Benéitez OL, Troya J, Buzón-Martín L, RELATIVITY Group.   +62 more
europepmc   +1 more source

Clinical performance of the urine‐based TERT promoter AbsoluteQ Digital PCR for non‐invasive detection of bladder cancer

Molecular Oncology, EarlyView.
A urine‐based digital PCR assay targeting two hotspot TERT promoter variants detected bladder cancer with high sensitivity and no false positives in this case–control cohort. The streamlined AbsoluteQ workflow outperformed Sanger sequencing and supports non‐invasive molecular testing for bladder cancer detection.
Anna Nykel, Izabela Kubiak, Lena Rutkowska, Żaneta Kasprzyk, Łukasz Kępczyński, Michał Bednarek, Dariusz Sobieraj, Jacek Wilkosz, Piotr Kania, Adam Jędrzejczyk, Bogdan Kałużewski, Agnieszka Gach, Tadeusz Kałużewski   +12 more
wiley   +1 more source

Modified Bekenstein Hawking Entropy of Five-Dimensioned Static Multi-Charge AdS Black Holes in Gauged Supergravity Theory. [PDF]

Entropy (Basel)
Wang C, Yang SZ.
europepmc   +1 more source

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

Molecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska, Stephany Gallardo, Nur S. Zainal, Leena Arora, Matthew Ellis, Maria‐Antoinette Lopez, Judith Austine, Sai Pittla, Serena J Chee, Aiman Alzetani, Emily C Shaw, Christian H Ottensmeier, Gareth J Thomas, Christopher J Hanley   +13 more
wiley   +1 more source

Thermodynamics and relativity [PDF]

Bulletin of the American Mathematical Society, 1933
openaire   +5 more sources

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

Molecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura, Tadahiro Kuribayashi, Johannes Brägelmann, Sachi Okawa, Masataka Taoka, Shunta Mori, Tomoka Nishimura, Takaaki Tanaka, Go Makimoto, Kiichiro Ninomiya, Kammei Rai, Eiki Ichihara, Ryohei Katayama, Katsuyuki Hotta, Masahiro Tabata, Yosuke Togashi, Yoshinobu Maeda, Martin L. Sos, Katsuyuki Kiura, Kadoaki Ohashi   +19 more
wiley   +1 more source